Table 2.
Feature | Discovery Group | Confirmation Group | ||
---|---|---|---|---|
AS, n = 16 |
Control, n = 14 |
AS, n = 27 |
Control, n = 27 |
|
Age, mean (SD) yrs | 36.01 (11.94) | 32.11 (7.34) | 36.08 (11.4) | 37.21 (10.68) |
No. male (%) | 12 (75) | 10 (71.43) | 14 (51.85) | 14 (51.85) |
No. Caucasian (%) | 13 (81.25) | 11 (78.57) | 17 (62.96) | 17 (62.96) |
Disease duration | 16.09 (12.87) | NA | 11.55 (5.86) | NA |
BASDAI* | 5.31 (2.01) | NA | 5.93 (1.35) | NA |
C-reactive protein | 1.4 (2.23) | NA | 1.56 (2.17) | NA |
Uveitis | 3 (18.75) | 0 | 14 (51.85) | 0 |
Psoriasis | 1 (6.25) | 0 | 3 (11.11) | 0 |
Peripheral inflammatory arthritis | 10 (62.5) | 0 | 7 (25.93) | 0 |
Crohn’s disease | 0 | 0 | 3 (11.11) | 0 |
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; NA: not applicable.